[To the Editor]{.smallcaps}---We read with great interest the article by Rawson et al recently published in this journal \[[@CIT0001]\]. In this article, the authors described low rates of pulmonary bacterial coinfection in patients with coronavirus disease 2019 (COVID-19). They also warn about the extensive use of broad-spectrum empirical antibiotics in critically ill COVID-19 patients, in the context of reduced routine microbiological investigation making antibiotic stewardship difficult. However, the low rate of coinfection described seems to us to be underestimated. We experienced in our center a much more important incidence of bacterial pneumonia, possibly related to the sampling method and the rate of sampling. Here we report bacterial pneumonia in critically ill patients with COVID-19 diagnosed by bacterial cultures of blind bronchoalveolar lavage (BBAL) \[[@CIT0002]\].

We conducted a prospective single-center study including every patient admitted to the Saint-Louis surgical intensive care unit (ICU) (Assistance Publique--Hôpitaux de Paris, Paris, France) for respiratory failure related to COVID-19. Exclusion criteria were age \<18 years, pregnancy, or moribundity patient at admission. Acute respiratory distress syndrome (ARDS) was defined according to the Berlin definition \[[@CIT0003]\]. COVID-19--associated ARDS was managed as recommended \[[@CIT0004]\]. Early-onset and late-onset ventilator-associated pneumonia (VAP) were defined as pneumonia diagnosed before and after 5 days of mechanical ventilation, respectively \[[@CIT0005]\].

All patients or their surrogate had an information about the data collection and gave their nonopposition to the study (ethical committee of the Société Française d'Anesthésie Réanimation, institutional review board 00010254-2019--203). Continuous variables were described as median while categorical variables were expressed as frequencies (%), and group comparisons of continuous variables were performed using Student *t* test. Categorical data were compared using χ ^2^ test for count data.

Of 54 COVID-19 patients admitted in our ICU from 20 March 2020 to 15 April 2020, 49 have been mechanically ventilated. Characteristics of patients are summarized in [Table 1](#T1){ref-type="table"}. In univariate analysis, patients with VAP had more ARDS, had more acute kidney injury, were mechanically ventilated longer, and had a longer ICU length of stay ([Table 1](#T1){ref-type="table"}).

###### 

Characteristics of Patients

  Characteristic                                       All Patients (N = 54)   Pneumonia (n = 20)   No Pneumonia (n = 34)   *P* Value
  ---------------------------------------------------- ----------------------- -------------------- ----------------------- -----------
  Age, y                                               63 (57--68)             64 (59--72)          62 (56--67)             .291
  Weight, kg                                           83 (75--94)             82 (72--89)          83 (77--95)             .407
  Height, cm                                           175 (166--178)          176 (168--180)       174 (165--178)          .341
  BMI, kg/m^2^                                         27 (26--30)             27 (23--29)          27 (26--32)             .288
  Male sex                                             42 (77.8)               16 (80.0)            26 (76.5)               .763
  Comorbidities                                                                                                             
   Tobacco use                                         5 (9.3)                 1 (5.0)              4 (11.8)                .408
   Hypertension                                        35 (64.8)               12 (60.0)            23 (67.6)               .570
   ACEI or ARB                                         19 (35.2)               6 (30.0)             13 (38.2)               .541
   Diabetes mellitus                                   21 (38.9)               8 (40.0)             13 (38.2)               .898
   Dyslipidemia                                        18 (33.3)               7 (35.0)             11 (32.4)               .842
   Coronary disease                                    5 (9.3)                 1 (5.0)              4 (11.8)                .408
   Chronic pulmonary disease                           7 (13.0)                2 (10.0)             5 (14.7)                .619
  Treatments before admission                                                                                               
   Antibiotics                                         35 (64.8)               12 (60.0)            23 (67.6)               .570
   Cephalosporin third generation                      26 (48.1)               9 (45.0)             17 (50.0)               .723
   Rovamycin                                           17 (31.5)               6 (30.0)             11 (32.4)               .857
   Amoxicillin-clavulanate                             3 (5.6)                 1 (5.0)              2 (5.9)                 .891
   Hydroxychloroquine                                  4 (7.4)                 1 (5.0)              3 (8.8)                 .604
   Azithromycin                                        10 (18.5)               2 (10.0)             8 (23.5)                .216
  Severity of illness, median (IQR)                                                                                         
   Delay between onset of symptoms and intubation, d   8 (3--11)               10 (5--12)           8 (1--11)               .299
   SAPS II                                             37 (27--46)             40 (29--56)          34 (27--43)             .209
   SOFA score                                          5 (4--7)                5 (4--7)             4 (3--6)                .279
  Organ failure                                                                                                             
   ARDS                                                46 (85.2)               20 (100.0)           26 (76.5)               .019
   Admission PaO~2~/FiO~2~                             126 (80--174)           115 (80--155)        141 (81--194)           .500
   Worst PaO~2~/FiO~2~                                 79 (70--114)            76 (70--101)         82 (68--136)            .476
   AKI                                                 28 (51.9)               14 (70.0)            14 (41.2)               .041
   RRT                                                 11 (20.4)               5 (25.0)             6 (17.6)                .517
  Outcome                                                                                                                   
   ICU mortality                                       15 (27.8)               6 (30.0)             9 (26.5)                .780
   Length of mechanical ventilation, d                 12 (7--21)              15 (11--32)          7 (5--20)               .046
   Length of stay in ICU, d                            12 (6--17)              17 (14--34)          9 (3--12)               .001

Continuous variables are described as median (interquartile range) and categorical variables as frequency (%).

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor blocker; ARDS, acute respiratory distress syndrome; BMI, body mass index; ICU, intensive care unit; PaO~2~/FiO~2~, arterial partial pressure of oxygen/fraction of inspired oxygen; RRT, renal replacement therapy; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment.

BBAL was performed in 45 patients during ICU stay; all were mechanically ventilated and suspected of bacterial pneumonia. Bacterial cultures of BBAL grew with significant amount of bacteria (ie, ≥10^4^ colony-forming units/mL) in 37% (n = 20) of patients. Bacterial pathogens causing pneumonia are summarized in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. Among the 20 bacterial pneumoniae, 4 (20%) were classified as community-acquired, 1 (5%) hospital-acquired, and 15 (75%) VAP including 3 early-onset and 12 late-onset. In early-onset VAP, bacterial pathogens were mostly gram-positive bacteria (2/3), and 67% (2/3) were susceptible to piperacillin-tazobactam, cefotaxime, cefepime, and meropenem. Conversely, in late-onset VAP, most bacterial pathogens were gram-negative bacteria (12/14) including 8 nonfermenting bacilli and 4 Enterobacterales. Among gram-negative bacteria causing late-onset VAP, 8% (1/12), 43% (5/12), 58% (7/12), and 83% (10/12) were susceptible to cefotaxime, piperacillin-tazobactam, cefepime, and meropenem, respectively.

We reported significant rate of bacterial pneumonia, mostly late-onset VAP, in critically ill patients with COVID-19 in our unit. We would emphasize the importance of performing respiratory samples to diagnose bacterial pneumonia and therefore based antimicrobial therapy on bacterial cultures. BBAL does not require bronchoscopy, decreasing the risk of contamination, and is suitable for bacterial culture. Recently, a new molecular test named FilmArray Pneumonia plus panel (BioFire, Salt Lake City, Utah) showed excellent performance compared to bacterial culture in bacterial pneumonia with rapid turnaround time \[[@CIT0006]\]. This new tool for detection of pathogens could lead to a reduction of spectrum and duration of antibiotic therapy.

Supplementary Data {#s1}
==================

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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